Leclaza Lazcluze
Named-patient access overview. Leclaza Lazcluze is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Leclaza Lazcluze
Leclaza / Lazcluze (lazertinib) is manufactured by Yuhan / J&J and indicated for EGFR+ 1L NSCLC (combo w/ amivantamab). It is a approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Leclaza Lazcluze
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Leclaza Lazcluze for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Leclaza Lazcluze is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Leclaza Lazcluze in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Start a request for Leclaza Lazcluze
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.